As it takes Lartruvo off the shelves, Lilly is setting up program to provide drug access to current patients

When Lilly’s approved soft tissue sarcoma drug Lartruvo unexpectedly failed to help patients live longer in a late-stage study in January, US and EU regulators discouraged new patients from starting treatment with the medicine, and the drugmaker suspended its promotion of the therapy.